Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 14/20 | 0.46 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.46 |
| ▸ | PIK3CD | O00329 | 13/20 | 0.41 |
| ▸ | KDR | P35968 | 13/20 | 0.41 |
| ▸ | ABL1 | P00519 | 12/20 | 0.41 |
| ▸ | HCK | P08631 | 12/20 | 0.41 |
| ▸ | SRC | P12931 | 12/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 12/20 | 0.41 |
| ▸ | PIK3CB | P42338 | 12/20 | 0.41 |
| ▸ | MTOR | P42345 | 12/20 | 0.41 |
| ▸ | PIK3CG | P48736 | 12/20 | 0.41 |
| ▸ | PRKDC | P78527 | 12/20 | 0.41 |
| ▸ | EPHB4 | P54760 | 11/20 | 0.41 |
| ▸ | PI4KB | Q9UBF8 | 9/20 | 0.41 |
| ▸ | BTK | Q06187 | 1/20 | 0.35 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.34 |
| ▸ | CSF1R | P07333 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23917520 | 0.78 | KDR (0.38) | EGFRPIK3CDKDRABL1HCK | |
| SCHEMBL16655465 | 0.73 | PIK3CD (0.43) | EGFRPIK3CDKDRABL1HCK | |
| SCHEMBL31736631 | 0.72 | EIF2AK3 (0.39) | EGFRERBB2CSF1R | |
| SCHEMBL31736378 | 0.72 | EIF2AK3 (0.39) | EGFRERBB2CSF1R | |
| SCHEMBL31736677 | 0.71 | EGFR (0.41) | EGFRERBB2KDRCSF1R | |
| SCHEMBL31736026 | 0.70 | EIF2AK3 (0.48) | EGFRERBB2 | |
| SCHEMBL31736262 | 0.70 | EIF2AK3 (0.48) | EGFRERBB2 | |
| SCHEMBL31735993 | 0.70 | EGFR (0.38) | EGFRERBB2KDRCSF1R | |
| SCHEMBL16701648 | 0.69 | F10 (0.36) | EGFRPIK3CDKDRABL1HCK | |
| SCHEMBL31736197 | 0.69 | MAPT (0.41) | EGFRERBB2KDRPI4KBLIMK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210317140-A1 | Heterocyclic Compounds and Methods of Use | MEDIVATION TECHNOLOGIES, INC. (US) | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210317140-A1 | Heterocyclic Compounds and Methods of Use | BTK, PIK3CD, PIK3CB | EGFR 828/4885ERBB2 95/4885PIK3CD 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.